Robin Taylor, Chief Commercial Officer of Agenus, shared a post on LinkedIn:
“Today I’m thrilled to share that Agenus is advancing BOT+BAL into the registrational Phase 3 ROBBIN study of neoadjuvant immunotherapy in high-risk resectable MSS colon cancer – one of the most prevalent and growing cancers, and now the number one cause of cancer death in people under the age of 50. This is a treatment setting for which there have been no major advances in over 20 years since the introduction of oxaliplatin to adjuvant therapy.
Thank you to our new and existing investors for making this work possible. I look forward to the mission ahead: changing the treatment paradigm and delivering on the promise of BOT+BAL for the patients who are counting on us.”